Anti-Cancer Effect of Quercetin in Xenograft Models with EBV-Associated Human Gastric Carcinoma.
Licorice extracts have been widely used in herbal and folk medications.Glycyrrhizacontains diverse range of biological compounds including triterpenes (glycyrrhizin, glycyrrhizic acid) and flavonoids (quercetin, liquiritin, liquiritigenin, glabridin, licoricidin, isoliquiritigenin). The flavonoids in licorice are known to have strong anti-cancer activities. Quercetin, the most abundant flavonoid, has been shown to have anti-ulcer, anti-cancer, antioxidant, and anti-inflammatory properties. Latent Epstein-Barr virus (EBV) infection can lead to serious malignancies, such as, Burkitt's lymphoma, Hodgkin's disease and gastric carcinoma(GC), and (Epstein-Barr virus associated gastric carcinoma) EBVaGC is one of the most common EBV-associated cancers. In this study, the authors first examined the anti-cancer effects of quercetin and isoliquiritigenin in vivo xenograft animal models implanted with EBV(+) human gastric carcinoma (SNU719) or EBV(-) human gastric carcinoma (MKN74), and then explored the molecular mechanisms responsible for their anti-cancer activities. The results obtained showed that anti-cancer effect of quercetin was greater than isoliquiritigenin in mice injected with EBV(+) human gastric carcinoma (SNU719) cells. On the other hand, quercetin and isoliquiritigenin had similar anti-cancer effects in mice injected with EBV(-) human gastric carcinoma (MKN74) cells. Interestingly, quercetin inhibited EBV viral protein expressions, including EBNA-1 and LMP-2 proteins in tumor tissues from mice injected with EBV(+) human gastric carcinoma. Quercetin more effectively induced p53-dependent apoptosis than isoliquiritigenin in EBV(+) human gastric carcinoma, and this induction was correlated with increased expressions of the cleaved forms of caspase-3, -9, and Parp. In EBV(-)human gastric carcinoma (MKN74), both quercetin and isoliquiritigenin induced the expressions of p53, Bax, and Puma and the cleaved forms of caspase-3 and -9 and Parp at similar levels.
College of Pharmacy, Duksung Women's University, Seoul 132-714, Korea. oeo3oeo@gmail.com.|Innovative Drug Center, Duksung Women's University, Seoul 132-714, Korea. oeo3oeo@gmail.com.
Hwan Hee
HH
Lee
College of Pharmacy, Duksung Women's University, Seoul 132-714, Korea. seulki0614@duksung.ac.kr.|Innovative Drug Center, Duksung Women's University, Seoul 132-714, Korea. seulki0614@duksung.ac.kr.
Seulki
S
Lee
Department of Medicinal Crop Research, National Institute of Horticultural and Herbal Science, Rural Development Administration, Eumseong 369-873, Korea. totoro69@korea.kr.
Yu Su
YS
Shin
College of Pharmacy, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University, Daegu 702-701, Korea. cmy1004g@naver.com.
Miyeon
M
Cho
College of Pharmacy, Research Institute of Pharmaceutical Sciences and Institute for Microorganisms, Kyungpook National University, Daegu 702-701, Korea. hkang72@gmail.com.
Hyojeung
H
Kang
College of Pharmacy, Duksung Women's University, Seoul 132-714, Korea. hyosun1102@duksung.ac.kr.|Innovative Drug Center, Duksung Women's University, Seoul 132-714, Korea. hyosun1102@duksung.ac.kr.
Hyosun
H
Cho
EBV; SNU719; human gastric carcinoma; p53; quercetin
Yakugaku Zasshi. 1999 Dec;119(12):945-55
10630100
Mol Pathol. 2000 Oct;53(5):255-61
11091849
Phytother Res. 2000 Dec;14(8):581-91
11113992
Planta Med. 2001 Nov;67(8):754-7
11731922
Biol Pharm Bull. 2002 Feb;25(2):247-50
11853176
Toxicology. 2003 Feb 1;183(1-3):133-42
12504347
J Steroid Biochem Mol Biol. 2002 Nov;82(4-5):315-22
12589938
Eur Urol. 2003 May;43(5):580-6
12706007
Nat Rev Cancer. 2004 Oct;4(10):757-68
15510157
Pharmacol Res. 2005 Jul;52(1):5-14
15911329
Acta Pharmacol Sin. 2007 Mar;28(3):404-9
17303004
Arch Pharm Res. 2007 Jul;30(7):820-6
17703732
Cancer Lett. 2008 Oct 8;269(2):315-25
18467024
Hepatol Res. 2009 Jan;39(1):60-9
18647187
Nutr Cancer. 2011;63(3):421-6
21391122
Cancer Chemother Pharmacol. 2011 Dec;68(6):1449-57
21479885
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jan;28(1):12-6
22230496
Cell. 2012 Jun 8;149(6):1269-83
22682249
J Agric Food Chem. 2014 Jan 22;62(3):542-53
24377378
Oxid Med Cell Longev. 2013;2013:596496
24379902
Microbiol Immunol. 2014 Mar;58(3):180-7
24397541
Lab Invest. 2014 Mar;94(3):262-74
24492281
Antiviral Res. 1989 Sep;12(2):99-110
2480745
J Biol Chem. 2014 Dec 26;289(52):35839-48
25368326
Cancers (Basel). 2014 Nov 07;6(4):2259-74
25386788
N Engl J Med. 1989 Oct 19;321(16):1080-5
2552313
PLoS One. 2015 May 26;10(5):e0128277
26011145
Oncotarget. 2015 May 20;6(14):12603-24
26059439
J Microbiol. 2015 Jul;53(7):468-74
26115996
Daru. 2015 Jul 04;23:35
26141646
Int Immunopharmacol. 2015 Sep;28(1):531-9
26218279
Ren Fail. 2015;37(9):1492-7
26338102
PLoS One. 2015 Oct 22;10(10):e0141370
26491966
Exp Ther Med. 2015 Aug;10(2):579-583
26622357
Cell Mol Life Sci. 2016 Aug;73(15):2829-50
26791483
Eur J Pharmacol. 2016 Jun 15;781:60-8
27041643
J Exp Clin Cancer Res. 2016 May 06;35:73
27151407
Oncol Rep. 2016 Jul;36(1):31-42
27175602
Arzneimittelforschung. 1995 Jun;45(6):697-700
7646573
Am J Pathol. 1993 Nov;143(5):1250-4
8238241